On September 3, 2024, the Shenzhen Public Resource Trading Center once again publicly solicited opinions on the "Continuation of Procurement Documents for Centralized Volume Purchase Agreement of Ultrasonic Knife Heads and Pre filled Catheter Flushers (Draft for Comments)". Enterprises can provide feedback before 17:00 on September 10.

The variety of this procurement is ultrasonic blade head (disposable/reusable/integrated handle ultrasonic blade head). After two years, this market is once again experiencing a tense moment.

The Guangdong Alliance's centralized procurement of ultrasonic knives will be launched, and market competition has entered a white hot stage

Since the first centralized procurement of ultrasonic cutting heads in Fujian Province in 2020, as of 2024, the centralized procurement areas for ultrasonic cutting heads have spread throughout the country. After this launch, the Guangdong Alliance will become the largest alliance for centralized procurement of ultrasonic knives.

At the end of 2021, Guangdong led a 16 province alliance to carry out bulk procurement of ultrasonic knife heads, unveiling the large-scale price reduction of ultrasonic knives. It is reported that the average price reduction of ultrasonic blade heads in Guangdong is 70.11%, with the highest price reduction being 93%. The average price of 7mm and 5mm ultrasonic blades has decreased from 5734 yuan to 1800 yuan, a decrease of 68.6%.

After the alliance was launched, the competitive landscape of China's ultrasonic knife market underwent significant changes. On the one hand, the market concentration CR4 has decreased from 74.8% in 2021 to 57.2% in 2024; On the other hand, under the influence of centralized volume based procurement, the market share of imported brands has declined to a certain extent.

According to statistics from Medical Equipment Shusheng, it is expected that the usage of ultrasound scalpel heads in China will exceed 14.6 million by 2028, tripling from 2023. Faced with such a hot market, the number of companies entering the ultrasound scalpel industry is also growing rapidly.

In the first half of this year, Mindray Medical topped the ultrasound knife equipment market with a market share of 29.82%. In the just concluded "3+N" pharmaceutical procurement alliance in the Beijing Tianjin Hebei region, Mindray Medical participated in the centralized procurement reporting for the first time, and the selected quantity ranked fifth among many manufacturers.

Adhering to clinical needs, Mindray helps domestic ultrasonic knives achieve "overtaking on curves"

China is a large country with a population of over 1.4 billion. The high prices of medical equipment led by foreign-funded enterprises will inevitably bring about high costs of medical consumption, which will go against the universal healthcare of "Healthy China 2030". To achieve the historical mission of universal healthcare for all, only Chinese national medical enterprises are the core force. At the same time, China's centralized procurement policy has created new opportunities for the development of domestic enterprises. With the gradual implementation of centralized procurement in our country, it will accelerate the "domestic substitution for imported" of medical devices.

Mindray's ultrasonic knife is not inferior to imported equipment in solving practical problems in clinical applications. Since its launch one year ago, the product has been widely recognized by users. And the company has put in a lot of effort in innovation and research and development, and its excellent product performance has won the favor of hospitals.

As a result, under the joint influence of multiple factors such as centralized procurement policies, innovative technologies, and close adherence to the market, domestic enterprises represented by Mindray have also begun to layout the ultrasonic knife track, and more and more capital has begun to increase support for domestic enterprises.

According to Mindray's latest financial report, Mindray Medical achieved a revenue of 20.531 billion yuan in the first half of 2024, an increase of 11.12% compared to the same period last year; The net profit attributable to the parent company was 7.561 billion yuan, an increase of 17.37% compared to the same period last year. Among them, the growth of minimally invasive surgery business even exceeded 90%. It can be seen that innovative medical companies led by Mindray have provided concrete possibilities for domestic ultrasonic knives to achieve "overtaking on the bend".

It is understood that Mindray's research and development innovation closely follows clinical needs, with a finely designed and easy-to-use blade that solves practical clinical needs. For example, some doctors have reported that "the existing ultrasound blade heads are somewhat clumsy and inadequate for performing delicate operations such as lymph node dissection." The R&D team needs to come up with the best solution, and based on the needs of dozens of surgical experts and Mindray's powerful innovation platform, Mindray innovatively designs a blade head that better meets the requirements of fine anatomy, successfully creating the first domestically produced fine blade head, which is about 20% thinner and narrower than the ultrasound blade heads featured by international first-class brands.

At the same time, the independently developed energy platform is not only an ultrasonic knife host but also an electric knife host. In July of this year, its host also added intelligent bipolar function, which can safely occlude 7mm blood vessels. The three in one host has a more streamlined design and reduces hospital procurement costs.

After thirty years of development, China's minimally invasive endoscopic surgery has entered the world's leading level. In the face of fierce market competition, independent research and development innovation and market selection determine the industry status of enterprises. In the future, we believe that under the leadership of Mindray, domestic ultrasonic knives will adhere to user needs as the guide, continue to innovate, maximize problem-solving for doctors and patients, actively respond to the centralized procurement policy, and more ethnic medical enterprises will contribute to the universal healthcare of "Healthy China 2030".

Innovative research and development technology, Mindray continuously improves the minimally invasive surgical landscape

Mindray is a leader in medical equipment in China, providing medical device products to the global market. Our main products cover three major fields: life information and support, in vitro diagnostics, and medical imaging, with the most comprehensive product line in the domestic industry.

According to statistics, Mindray's market share in most sub products of the life information and support business, such as monitors, ventilators, defibrillators, anesthesia machines, infusion pumps, lamp bed towers, etc., has become the first in China; The market share of blood cell business has firmly established itself as the first in China; The market share of ultrasound business has firmly established itself as the second largest in China.

It is worth noting that as a leading domestic medical device manufacturer, Mindray has been focusing on minimally invasive surgery since 2012.

After entering the field of minimally invasive surgery, we chose hard mirrors as the core entry point and invested heavily in research and development. Through our efforts in the field of hard mirror systems, we continuously improved the layout of minimally invasive surgery, extended the planning of the entire development of minimally invasive surgery, and created an integrated solution for minimally invasive surgery. Mindray will gradually launch products related to minimally invasive surgery, such as ultrasonic knives, energy platforms, disposable high-frequency electrocoagulation cutting electrodes, and laparoscopic surgical instruments, by the end of 2022, in order to improve its product layout in minimally invasive surgery.

Source: https://news.yaozh.com/archive/44208.html